IBDEI0AF ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4350,0)
 ;;=99606^^29^268^1^^^^1
 ;;^UTILITY(U,$J,358.3,4350,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4350,1,2,0)
 ;;=2^MTMS BY PHARM,INIT 15 MIN
 ;;^UTILITY(U,$J,358.3,4350,1,3,0)
 ;;=3^99606
 ;;^UTILITY(U,$J,358.3,4351,0)
 ;;=99607^^29^268^2^^^^1
 ;;^UTILITY(U,$J,358.3,4351,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4351,1,2,0)
 ;;=2^MTMS BY PHARM, EA ADDL 15 MIN
 ;;^UTILITY(U,$J,358.3,4351,1,3,0)
 ;;=3^99607
 ;;^UTILITY(U,$J,358.3,4352,0)
 ;;=98960^^29^269^1^^^^1
 ;;^UTILITY(U,$J,358.3,4352,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4352,1,2,0)
 ;;=2^INDIVIDUAL PATIENT, EA 30 MIN
 ;;^UTILITY(U,$J,358.3,4352,1,3,0)
 ;;=3^98960
 ;;^UTILITY(U,$J,358.3,4353,0)
 ;;=98961^^29^269^2^^^^1
 ;;^UTILITY(U,$J,358.3,4353,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4353,1,2,0)
 ;;=2^2-4 PATIENTS, EA 30 MIN
 ;;^UTILITY(U,$J,358.3,4353,1,3,0)
 ;;=3^98961
 ;;^UTILITY(U,$J,358.3,4354,0)
 ;;=98962^^29^269^3^^^^1
 ;;^UTILITY(U,$J,358.3,4354,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4354,1,2,0)
 ;;=2^5-8 PATIENTS, EA 30 MIN
 ;;^UTILITY(U,$J,358.3,4354,1,3,0)
 ;;=3^98962
 ;;^UTILITY(U,$J,358.3,4355,0)
 ;;=S9810^^29^270^1^^^^1
 ;;^UTILITY(U,$J,358.3,4355,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,4355,1,2,0)
 ;;=2^Infusion/Drug Admin per Hr
 ;;^UTILITY(U,$J,358.3,4355,1,3,0)
 ;;=3^S9810
 ;;^UTILITY(U,$J,358.3,4356,0)
 ;;=D68.318^^30^271^14
 ;;^UTILITY(U,$J,358.3,4356,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4356,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Intrinsic Circ Anticoagulants
 ;;^UTILITY(U,$J,358.3,4356,1,4,0)
 ;;=4^D68.318
 ;;^UTILITY(U,$J,358.3,4356,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,4357,0)
 ;;=D68.9^^30^271^12
 ;;^UTILITY(U,$J,358.3,4357,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4357,1,3,0)
 ;;=3^Coagulation Defect,Unspec
 ;;^UTILITY(U,$J,358.3,4357,1,4,0)
 ;;=4^D68.9
 ;;^UTILITY(U,$J,358.3,4357,2)
 ;;=^5002364
 ;;^UTILITY(U,$J,358.3,4358,0)
 ;;=D68.8^^30^271^13
 ;;^UTILITY(U,$J,358.3,4358,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4358,1,3,0)
 ;;=3^Coagulation Defects,Other Spec
 ;;^UTILITY(U,$J,358.3,4358,1,4,0)
 ;;=4^D68.8
 ;;^UTILITY(U,$J,358.3,4358,2)
 ;;=^5002363
 ;;^UTILITY(U,$J,358.3,4359,0)
 ;;=D68.51^^30^271^1
 ;;^UTILITY(U,$J,358.3,4359,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4359,1,3,0)
 ;;=3^Activated Protein C Resistance
 ;;^UTILITY(U,$J,358.3,4359,1,4,0)
 ;;=4^D68.51
 ;;^UTILITY(U,$J,358.3,4359,2)
 ;;=^5002358
 ;;^UTILITY(U,$J,358.3,4360,0)
 ;;=D68.59^^30^271^24
 ;;^UTILITY(U,$J,358.3,4360,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4360,1,3,0)
 ;;=3^Primary Thrombophilia
 ;;^UTILITY(U,$J,358.3,4360,1,4,0)
 ;;=4^D68.59
 ;;^UTILITY(U,$J,358.3,4360,2)
 ;;=^5002360
 ;;^UTILITY(U,$J,358.3,4361,0)
 ;;=D68.61^^30^271^5
 ;;^UTILITY(U,$J,358.3,4361,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4361,1,3,0)
 ;;=3^Antiphospholipid Syndrome
 ;;^UTILITY(U,$J,358.3,4361,1,4,0)
 ;;=4^D68.61
 ;;^UTILITY(U,$J,358.3,4361,2)
 ;;=^185421
 ;;^UTILITY(U,$J,358.3,4362,0)
 ;;=D68.62^^30^271^18
 ;;^UTILITY(U,$J,358.3,4362,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4362,1,3,0)
 ;;=3^Lupus Anticoagulant Syndrome
 ;;^UTILITY(U,$J,358.3,4362,1,4,0)
 ;;=4^D68.62
 ;;^UTILITY(U,$J,358.3,4362,2)
 ;;=^5002361
 ;;^UTILITY(U,$J,358.3,4363,0)
 ;;=I26.99^^30^271^25
 ;;^UTILITY(U,$J,358.3,4363,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4363,1,3,0)
 ;;=3^Pulmonary Embolism w/o Acute Cor Pulmonale
 ;;^UTILITY(U,$J,358.3,4363,1,4,0)
 ;;=4^I26.99
 ;;^UTILITY(U,$J,358.3,4363,2)
 ;;=^5007150
 ;;^UTILITY(U,$J,358.3,4364,0)
 ;;=I42.8^^30^271^8
 ;;^UTILITY(U,$J,358.3,4364,1,0)
 ;;=^358.31IA^4^2
